DTaP-vaccine, therapeutic useResearch-and-developmentDiphtheria-tetanus-and-pertussis-vaccine, therapeuDiphtheria, preventionPertussis, preventionTetanus, preventionCost-effectivenessInfantsChildrenCost-benefitdoi:10.1007/BF03275582NA;Springer International PublishingPharmacoeconomics & Outcomes News...
An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to co... :To evaluate the health impact and coat effectiveness of two infant vaccination strategies for protection against hepatitis B virus (HBV) ...
Second dose of DTaP vaccine not cost effective in USPharmacoEconomics & Outcomes News -doi:10.1007/s40274-016-2879-6NoneSpringer International PublishingPharmacoeconomics & Outcomes News
DTaPVaccinationQuality-adjusted life yearBackground: Both re-emergence of pertussis outbreak among adolescents/adults and recent approval of the extended use of DTaP vaccine for boosting adolescents/adults against pertussis in Japan, have raised the possibility of using aP-containing vaccine in pregnant ...
Estimating the potential health gain and cost consequences of introducing a pre-school DTaP pertussis booster into the UK child vaccination schedule. Vaccine 2002; 20: 1778–86 View ArticleStevenson M, Beard S, Finn A, Brennan A. Estimating the potential health gain and cost conse- quences of...
Economic Evaluation of Diphtheria, Tetanus, and Acellular Pertussis (DTaP) Vaccine in the United States: A Cost-Benefit and Cost-Effectiveness Model with Visual Basic ApplicationThe American Pediatric Society and the Society for Pediatric Research 1999 Abstract...
Stevenson M, Beard S, Finn A, et al. Estimating the potential health gain and cost consequences of introducing a pre-school DTaP pertussis booster into the UK child vaccination schedule. Vaccine 2002; 20: 1778–86 View ArticleStevenson M, Beard S, Finn A, Brennan A. Estimating the ...
The resulting analysis shows that DTaP-IPV/HIb could have been more competitively priced compared with the combination vaccine DTaP-HepB-IPV, for federal contract prices in 2009, 2010 and 2011. This study also proposes the lowest overall cost formularies when shortages of monovalent vaccines occur...
Economic Evaluation of Diphtheria, Tetanus, and Acellular Pertussis (DTaP) Vaccine in the United States: A Cost-Benefit and Cost-Effectiveness Model with Visual Basic Applicationdoi:10.1203/00006450-199904020-00728Donaus kwumPr SrSphn Hadr...
DTaP-vaccine, therapeutic usePertussis, preventionA vaccination strategy for the prevention of pertussis in healthy adults is cost effective, and potentially cost saving, from the perspective of German society, according to results from a Markov model. Researchers used a previously constructed model to...